Cargando…

Increased expression of the immunosuppressive interleukin-35 in patients with non-small cell lung cancer

BACKGROUND: The immunosuppressive role of the cytokine IL-35 in patients with non-small cell lung cancer (NSCLC) is poorly understood. In this study, we analysed the localisation and regulation of IL-35 in the lung of patients with non-small cell lung cancer (NSCLC) to further elucidate the immune-e...

Descripción completa

Detalles Bibliográficos
Autores principales: Heim, Lisanne, Kachler, Katerina, Siegmund, Raphaela, Trufa, Denis I., Mittler, Susanne, Geppert, Carol-Immanuel, Friedrich, Juliane, Rieker, Ralf J., Sirbu, Horia, Finotto, Susetta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6734661/
https://www.ncbi.nlm.nih.gov/pubmed/30956278
http://dx.doi.org/10.1038/s41416-019-0444-3
_version_ 1783450190437416960
author Heim, Lisanne
Kachler, Katerina
Siegmund, Raphaela
Trufa, Denis I.
Mittler, Susanne
Geppert, Carol-Immanuel
Friedrich, Juliane
Rieker, Ralf J.
Sirbu, Horia
Finotto, Susetta
author_facet Heim, Lisanne
Kachler, Katerina
Siegmund, Raphaela
Trufa, Denis I.
Mittler, Susanne
Geppert, Carol-Immanuel
Friedrich, Juliane
Rieker, Ralf J.
Sirbu, Horia
Finotto, Susetta
author_sort Heim, Lisanne
collection PubMed
description BACKGROUND: The immunosuppressive role of the cytokine IL-35 in patients with non-small cell lung cancer (NSCLC) is poorly understood. In this study, we analysed the localisation and regulation of IL-35 in the lung of patients with non-small cell lung cancer (NSCLC) to further elucidate the immune-escape of cancer cells in perioperative course of disease. METHODS: Interleukin 35 (IL-35) was measured by ELISA in postoperative serum from 7 patients with NSCLC as well as 8 samples from healthy controls. Immunohistochemistry, FACS analysis, real-time PCR, as well as western blot from samples of the control (CTR), peri-tumoural (PT) and the tumoural (TU) region of the lung derived from patients with NSCLC and 10 controls were performed. RESULTS: Here we found elevated levels of IL-35 in the TU region as well as postoperative serum from patients with lung adenocarcinoma. Consistently, we found an increased expression of IL-35(+)Foxp-3(+) cells, which associated with ARG1 mRNA expression and decreased TNFA in the TU region of the lung of patients with NSCLC as compared to their CTR region. Furthermore, in the CTR region of the lung of patients with NSCLC, CD68(+) macrophages were induced and correlated with IL-35(+) cells. Finally, IL-35 positively correlated with TTF-1(+)PD-L1(+) cells in the TU region of NSCLC patients. CONCLUSIONS: Induced IL-35(+)Foxp3(+) cell numbers in the TU region of the lung of patients with NSCLC associated with ARG1 mRNA expression and with TTF-1(+)PD-L1(+) cells. In the tumour-free CTR area, IL-35 correlated with CD68(+) macrophages. Thus inhibitors to IL-35 would probably succeed in combination with antibodies against immune checkpoints like PD-L1 and PD-1 currently used against NSCLC because they would inhibit immunosuppressive macrophages and T regulatory cells while promoting T cell-mediated anti-tumoural immune responses in the microenvironment as well as the TU region of NSCLC patients.
format Online
Article
Text
id pubmed-6734661
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-67346612020-04-08 Increased expression of the immunosuppressive interleukin-35 in patients with non-small cell lung cancer Heim, Lisanne Kachler, Katerina Siegmund, Raphaela Trufa, Denis I. Mittler, Susanne Geppert, Carol-Immanuel Friedrich, Juliane Rieker, Ralf J. Sirbu, Horia Finotto, Susetta Br J Cancer Article BACKGROUND: The immunosuppressive role of the cytokine IL-35 in patients with non-small cell lung cancer (NSCLC) is poorly understood. In this study, we analysed the localisation and regulation of IL-35 in the lung of patients with non-small cell lung cancer (NSCLC) to further elucidate the immune-escape of cancer cells in perioperative course of disease. METHODS: Interleukin 35 (IL-35) was measured by ELISA in postoperative serum from 7 patients with NSCLC as well as 8 samples from healthy controls. Immunohistochemistry, FACS analysis, real-time PCR, as well as western blot from samples of the control (CTR), peri-tumoural (PT) and the tumoural (TU) region of the lung derived from patients with NSCLC and 10 controls were performed. RESULTS: Here we found elevated levels of IL-35 in the TU region as well as postoperative serum from patients with lung adenocarcinoma. Consistently, we found an increased expression of IL-35(+)Foxp-3(+) cells, which associated with ARG1 mRNA expression and decreased TNFA in the TU region of the lung of patients with NSCLC as compared to their CTR region. Furthermore, in the CTR region of the lung of patients with NSCLC, CD68(+) macrophages were induced and correlated with IL-35(+) cells. Finally, IL-35 positively correlated with TTF-1(+)PD-L1(+) cells in the TU region of NSCLC patients. CONCLUSIONS: Induced IL-35(+)Foxp3(+) cell numbers in the TU region of the lung of patients with NSCLC associated with ARG1 mRNA expression and with TTF-1(+)PD-L1(+) cells. In the tumour-free CTR area, IL-35 correlated with CD68(+) macrophages. Thus inhibitors to IL-35 would probably succeed in combination with antibodies against immune checkpoints like PD-L1 and PD-1 currently used against NSCLC because they would inhibit immunosuppressive macrophages and T regulatory cells while promoting T cell-mediated anti-tumoural immune responses in the microenvironment as well as the TU region of NSCLC patients. Nature Publishing Group UK 2019-04-08 2019-04-30 /pmc/articles/PMC6734661/ /pubmed/30956278 http://dx.doi.org/10.1038/s41416-019-0444-3 Text en © Cancer Research UK 2019 https://creativecommons.org/licenses/by/4.0/This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).
spellingShingle Article
Heim, Lisanne
Kachler, Katerina
Siegmund, Raphaela
Trufa, Denis I.
Mittler, Susanne
Geppert, Carol-Immanuel
Friedrich, Juliane
Rieker, Ralf J.
Sirbu, Horia
Finotto, Susetta
Increased expression of the immunosuppressive interleukin-35 in patients with non-small cell lung cancer
title Increased expression of the immunosuppressive interleukin-35 in patients with non-small cell lung cancer
title_full Increased expression of the immunosuppressive interleukin-35 in patients with non-small cell lung cancer
title_fullStr Increased expression of the immunosuppressive interleukin-35 in patients with non-small cell lung cancer
title_full_unstemmed Increased expression of the immunosuppressive interleukin-35 in patients with non-small cell lung cancer
title_short Increased expression of the immunosuppressive interleukin-35 in patients with non-small cell lung cancer
title_sort increased expression of the immunosuppressive interleukin-35 in patients with non-small cell lung cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6734661/
https://www.ncbi.nlm.nih.gov/pubmed/30956278
http://dx.doi.org/10.1038/s41416-019-0444-3
work_keys_str_mv AT heimlisanne increasedexpressionoftheimmunosuppressiveinterleukin35inpatientswithnonsmallcelllungcancer
AT kachlerkaterina increasedexpressionoftheimmunosuppressiveinterleukin35inpatientswithnonsmallcelllungcancer
AT siegmundraphaela increasedexpressionoftheimmunosuppressiveinterleukin35inpatientswithnonsmallcelllungcancer
AT trufadenisi increasedexpressionoftheimmunosuppressiveinterleukin35inpatientswithnonsmallcelllungcancer
AT mittlersusanne increasedexpressionoftheimmunosuppressiveinterleukin35inpatientswithnonsmallcelllungcancer
AT geppertcarolimmanuel increasedexpressionoftheimmunosuppressiveinterleukin35inpatientswithnonsmallcelllungcancer
AT friedrichjuliane increasedexpressionoftheimmunosuppressiveinterleukin35inpatientswithnonsmallcelllungcancer
AT riekerralfj increasedexpressionoftheimmunosuppressiveinterleukin35inpatientswithnonsmallcelllungcancer
AT sirbuhoria increasedexpressionoftheimmunosuppressiveinterleukin35inpatientswithnonsmallcelllungcancer
AT finottosusetta increasedexpressionoftheimmunosuppressiveinterleukin35inpatientswithnonsmallcelllungcancer